NanoViricides, Inc.
NNVCHealthcare|Biotechnology|US
$1.32
+0.03 (+2.33%)
DCF Value
$0.12
Tangible Book / Share
$0.41
Cash / Share
$0.14
Financials
Financial Snapshot
Market Cap
$33.7M
Enterprise Value
$30.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$8.2M
Cash & Investments
$2.8M
Net Cash
$2.8M
Free Cash Flow (TTM)
$3199.75B
Operating CF (TTM)
$3115.44B
Debt/Equity
0.00
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $15.1M | $7.1M | $2.6M | $13.7M | $20.5M | $14.1M | $8.1M | $4.8M | $1.6M | $2.8M | $2.8M | |
| Operating Cash Flow | -$7.9M | -$7.8M | -$6.8M | -$6.7M | -$8.2M | -$5.9M | -$5.7M | -$6.3M | -$8.5M | -$7696.02B | $3115.44B | |
| Free Cash Flow | -$8.1M | -$8.0M | -$6.9M | -$6.7M | -$8.5M | -$6.2M | -$5.8M | -$6.5M | -$8.5M | -$7780.33B | $3199.75B | |
| Capital Expenditure | -$165.0K | -$241.8K | -$73.8K | -$8.6K | -$238.8K | -$324.3K | -$151.7K | -$156.6K | -$57.0K | -$84.32B | $84.32B | |
| Financing Cash Flow | -$1.0M | $4.6M | $2.4M | $17.8M | $15.3M | -$234.7K | -$94.8K | $3.1M | $5.3M | $9015.88B | $9.0M |
R&D Spending
R&D (TTM)
$2595.91B
R&D Intensity
—
R&D Growth vs Prior
-44.9%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $5.5M | $4.8M | $5.9M | $4.7M | $6.1M | $5.8M | $6.4M | $5.4M | $5.5M | $4707.63B | $2595.91B | |
| SG&A | $4.1M | $4.5M | $2.7M | $3.3M | $2.6M | $2.3M | $2.6M | $3.1M | $4.0M | $3598.74B | $3598.74B |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $663.0K | $680.1K | $695.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $525.3K | $259.4K | |
| Gross Profit | -$663.0K | -$680.1K | -$695.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$525.3K | -$259.4K | |
| R&D | $5.5M | $4.8M | $5.9M | $4.7M | $6.1M | $5.8M | $6.4M | $5.4M | $5.5M | $4707.63B | $2595.91B | |
| SG&A | $4.1M | $4.5M | $2.7M | $3.3M | $2.6M | $2.3M | $2.6M | $3.1M | $4.0M | $3598.74B | $3598.74B | |
| Operating Income | -$9.6M | -$9.3M | -$8.7M | -$8.0M | -$8.7M | -$8.1M | -$8.9M | -$8.5M | -$9.6M | -$8.3M | -$8.3M | |
| Interest Expense | $2.1M | $544.5K | $0.00 | $93.7K | $85.4K | $5.1K | $938.00 | $49.8K | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$10.3M | -$8.6M | -$8.4M | -$13.4M | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M | -$8.2M | -$8.2M | |
| Net Income | -$10.3M | -$8.6M | -$8.2M | -$13.4M | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M | -$8.2M | -$8.2M | |
| EPS (Diluted) | -3.43 | -2.64 | -2.30 | -2.39 | -0.81 | -0.70 | -0.74 | -0.70 | -0.63 | -0.41 | -0.41 | |
| EBITDA | -$8.9M | -$8.6M | -$8.0M | -$7.3M | -$8.0M | -$7.4M | -$7.8M | -$7.5M | -$8.7M | -$7.8M | -$7.7M | |
| Shares Out. (M) | 3.01 | 3.25 | 3.59 | 5.62 | 10.90 | 11.53 | 11.63 | 11.87 | 15.12 | 20.19 | 20.19 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.1M | $7.1M | $2.6M | $13.7M | $20.5M | $14.1M | $8.1M | $4.8M | $1.6M | $2.8M | $2.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $15.3M | $7.3M | $2.8M | $14.0M | $20.8M | $14.4M | $8.4M | $5.0M | $1.7M | $3.2M | $3.2M | |
| Total Assets | $27.0M | $18.5M | $13.4M | $23.9M | $30.3M | $23.5M | $16.9M | $12.8M | $8.8M | $9.9M | $9.9M | |
| Total Current Liabilities | $4.7M | $881.9K | $2.8M | $2.2M | $351.1K | $412.8K | $534.3K | $1.4M | $1.3M | $1.2M | $1.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.7M | $881.9K | $2.8M | $2.2M | $351.1K | $412.8K | $2.0M | $1.4M | $1.3M | $1.2M | $1.2M | |
| Stockholders' Equity | $20.3M | $17.7M | $10.6M | $21.8M | $29.9M | $23.1M | $14.9M | $11.5M | $7.5M | $8.7M | $8.7M | |
| Retained Earnings | -$75.1M | -$83.7M | -$92.1M | -$105.6M | -$114.4M | -$122.5M | -$131.1M | -$139.4M | -$148.8M | -$157.1M | -$157.1M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.9M | -$7.8M | -$6.8M | -$6.7M | -$8.2M | -$5.9M | -$5.7M | -$6.3M | -$8.5M | -$7696.02B | $3115.44B | |
| Capital Expenditure | -$165.0K | -$241.8K | -$73.8K | -$8.6K | -$238.8K | -$324.3K | -$151.7K | -$156.6K | -$57.0K | -$84.32B | $84.32B | |
| Free Cash Flow | -$8.1M | -$8.0M | -$6.9M | -$6.7M | -$8.5M | -$6.2M | -$5.8M | -$6.5M | -$8.5M | -$7780.33B | $3199.75B | |
| Investing Cash Flow | -$165.0K | -$241.8K | -$73.8K | -$8.6K | -$238.8K | -$324.3K | -$151.7K | -$156.6K | -$57.0K | -$84.32B | -$84.3K | |
| Financing Cash Flow | -$1.0M | $4.6M | $2.4M | $17.8M | $15.3M | -$234.7K | -$94.8K | $3.1M | $5.3M | $9015.88B | $9.0M | |
| Issuance of Stock | $5.0M | $4.6M | $2.4M | $16.7M | $16.6M | $0.00 | $0.00 | $3.1M | $5.3M | $9.0M | $9.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$1.0M | $0.00 | $0.00 | $1.2M | -$1.3M | -$234.7K | -$94.8K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.6M | $791.2K | $532.3K | $559.4K | $405.6K | $338.4K | $214.2K | $222.2K | $223.3K | $49.62B | -$124.6M | |
| Net Change in Cash | -$9.1M | -$8.0M | -$4.5M | $11.2M | $6.8M | -$6.5M | -$5.9M | -$3.4M | -$3.2M | $1235.55B | $1.2M |
Dilution Tracker
Shares outstanding grew 85.2% over 5 years — significant dilution
Shares Outstanding
26M
5-Year Share Growth
+85.2%
Stock Issuance (TTM)
$9.0M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 3.01 | 3.25 | 3.59 | 5.62 | 10.90 | 11.53 | 11.63 | 11.87 | 15.12 | 20.19 | 20.19 | |
| Change vs Prior % | — | 8.0% | 10.6% | 56.5% | 94.1% | 5.8% | 0.8% | 2.1% | 27.3% | 33.5% | 0.0% | |
| Stock Issuance | $5.0M | $4.6M | $2.4M | $16.7M | $16.6M | $0.00 | $0.00 | $3.1M | $5.3M | $9.0M | $9.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.6M | $791.2K | $532.3K | $559.4K | $405.6K | $338.4K | $214.2K | $222.2K | $223.3K | $49.62B | -$124.6M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -50.7% | -48.5% | -77.8% | -61.8% | -29.5% | -35.1% | -57.8% | -72.3% | -125.9% | -94.7% | -91.1% | |
| ROA % | -38.2% | -46.2% | -61.3% | -56.2% | -29.2% | -34.5% | -50.8% | -64.7% | -107.3% | -83.2% | -83.2% | |
| ROIC % | -36.5% | -52.8% | -79.9% | -34.9% | -29.1% | -35.0% | -54.6% | -74.3% | -127.6% | -95.7% | -95.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -0.5% | -2.6% | -2.3% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -8.4% | 2.9% | 7.1% | 7.7% | -9.3% | 7.2% | -10.2% | 4.8% | -12.6% | 13.4% | |
| Net Income | 3.9% | 16.9% | 3.7% | -63.1% | 34.4% | 8.1% | -5.9% | 3.4% | -14.1% | 13.2% | |
| EPS (Diluted) | 7.8% | 23.0% | 12.9% | -3.9% | 66.1% | 13.6% | -5.7% | 5.4% | 10.0% | 34.9% | |
| Operating Cash Flow | -15.6% | 1.5% | 12.5% | 2.0% | -23.2% | 28.3% | 3.8% | -11.4% | -34.3% | -90768933.7% | |
| Free Cash Flow | -10.4% | 0.6% | 14.2% | 2.9% | -26.6% | 26.5% | 6.3% | -11.2% | -31.9% | -91150994.3% | |
| R&D Expense | 10.0% | -12.7% | 22.7% | -20.7% | 30.2% | -5.4% | 10.5% | -14.9% | 2.1% | 84835713.9% | |
| SG&A Expense | 6.2% | 10.6% | -39.1% | 20.6% | -20.3% | -11.4% | 9.5% | 20.7% | 31.3% | 89021466.6% | |
| Total Assets | -26.3% | -31.3% | -27.5% | 77.8% | 26.5% | -22.4% | -28.1% | -24.1% | -31.2% | 11.9% | |
| Book Value / Share | -15.4% | -19.5% | -45.7% | 31.2% | -29.2% | -27.1% | -36.1% | -24.5% | -48.5% | -13.5% | |
| Debt | -54.0% | -100.0% | 0.0% | 0.0% | -91.7% | -0.5% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 4.2% | 8.0% | 10.6% | 56.5% | 94.1% | 5.8% | 0.8% | 2.1% | 27.3% | 33.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B3.07
10Y Low / Med / High0.90 / 1.92 / 3.99
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCF0.00
Intrinsic Value Models (per share)
DCF Value
$0.12
Tangible Book / Share
$0.41
Net Current Assets / Share
$0.08
Graham Net-Net
$0.08
Cash / Share
$0.14
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -7.87 | -3.33 | -2.07 | -3.13 | -5.73 | -2.69 | -1.55 | -2.64 | -2.22 | -3.37 | -3.20 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 3.99 | 1.62 | 1.61 | 1.93 | 1.69 | 0.94 | 0.90 | 1.92 | 2.82 | 3.21 | 3.07 | |
| EV/EBITDA | -7.83 | -2.50 | -1.82 | -4.04 | -3.75 | -1.05 | -0.67 | -2.29 | -2.25 | -3.22 | -4.00 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-7.81
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $7.0M | $76.5M | $133.5M |
| Net Income | -$9.3M | $10.1M | $19.2M |
| EPS | $-0.46 | $0.50 | $0.95 |
| # Analysts (EPS) | 1 | 1 | 1 |